Cullinan Therapeutics, Inc. Income Statement
CGEM / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 |
| SG&A Expense | $54.0M | $42.5M | $40.2M | $17.1M | $17.1M |
| R&D Expense | $142.9M | $148.2M | $91.9M | $43.2M | $43.2M |
| Operating Income | -$196.9M | -$191.1M | $144.6M | -$60.3M | -$60.3M |
| Income Tax | $117.0K | -$14.1M | $42.1M | - | - |
| Net Income | -$167.4M | -$153.2M | $111.2M | -$51.8M | -$51.8M |
| EPS (Basic) | - | -$3.69 | $2.46 | - | - |
| EPS (Diluted) | - | -$3.69 | $2.38 | -$2.60 | - |
| Shares Outstanding | 58.5M | 41.5M | 45.8M | 29.8M | 19.9M |